Nicorandil alleviated cardiac hypoxia/reoxygenation-induced cytotoxicity via upregulating ketone body metabolism and ACAT1 activity

Yan Ping Bai¹ and Lei Sen Han²,*

¹Department of Cardiology, The Affiliated Hospital of Yan’an University, Yan’an 716000, ²Department of Cardiology, The Forth Renmin Hospital of Xi’an, Shanxi Province 710004, China

ARTICLE INFO
Received January 28, 2018
Revised May 2, 2018
Accepted May 23, 2018

*Correspondence
Lei Sen Han
E-mail: hanleisen196601@126.com

Key Words
Acetyl-CoA acetyltransferase
Hypoxia reoxygenation
Ketone body
Nicorandil
OXCT1

ABSTRACT To study the effect of nicorandil pretreatment on ketone body metabolism and Acetyl-CoA acetyltransferase (ACAT1) activity in hypoxia/reoxygenation (H/R)-induced cardiomyocytes. In our study, we applied H9c2 cardiomyocytes cell line to evaluate the cardioprotective effects of nicorandil. We detected mitochondrial viability, cellular apoptosis, reactive oxygen species (ROS) production and calcium overloading in H9c2 cells that exposed to H/R-induced cytotoxicity. Then we evaluated whether nicorandil possibly regulated ketone body, mainly β-hydroxybutyrate (BHB) and acetoacetate (ACAC), metabolism by regulating ACAT1 and Succinyl-CoA:3-ketoacid coenzyme A transferase 1 (OXCT1) protein and gene expressions. Nicorandil protected H9c2 cardiomyocytes against H/R-induced cytotoxicity dose-dependently by mitochondria-mediated anti-apoptosis pathway. Nicorandil significantly decreased cellular apoptotic rate and enhanced the ratio of Bcl-2/Bax expressions. Further, nicorandil decreased the production of ROS and alleviated calcium overloading in H/R-induced H9c2 cells. In crucial, nicorandil upregulated ACAT1 and OXCT1 protein expressions and either of their gene expressions, contributing to increased production of cellular BHB and ACAC. Nicorandil alleviated cardiomyocytes H/R-induced cytotoxicity through upregulating ACAT1/OXCT1 activity and ketone body metabolism, which might be a potential mechanism for emerging study of nicorandil and other K<sub>ATP</sub> channel openers.

INTRODUCTION

Ischemia/reperfusion injury (IRI) caused myocardial detrimental damage by following blood restoration after coronary occlusion [1]. The most crucial inducers were calcium overloading and excessive ROS produced by mitochondria whose oxidative phosphorylation lost its normal function after reperfusion [2]. One of the clinical/experimental interventions was ischemic preconditioning (IPC) which targeted to mitochondrial ATP-sensitive potassium channel (K<sub>ATP</sub> channel), having been found could reduce the infarct size of heart left ventricular exposed to (IRI) [3]. Mechanism study had uncovered that selectively activating K<sub>ATP</sub> channel by pharmacological intervention displayed the approximately effects of IPC in alleviating IRI [4]. Although IPC decreased ROS production after IRI, heart was an energy-consumption organ that demanded other energy metabolism for sufficient power supplying.

Ketone body was considered as a significant contributor to cellular and organic energy metabolism in biological states. Especially in pathological condition, ketone body acted as an important energetic source in mammalians when oxidative phosphorylation was damaged. Ketone body, consisted with 3-hydroxybutyrate
which promisingly characterized the potential activities of K
of ACAT1 and OXCT1, and either of ketone body metabolism,
andil pretreatment upregulated protein and gene expressions
mitochondria-mediated proapoptotic pathway. In crucial, nicor-
alleviated calcium overloading and reduced cellular apoptosis in
posed to H/R. Meantime, nicorandil decreased ROS production,
increased cellular and mitochondrial viability in H9c2 cells ex-
effects of nicorandil on H/R-induced cytotoxicity. Nicorandil
protective effects through the ketone body metabolism in H/R-
and preventing oxidative stress-induced cellular apoptosis
hibiting good cardioprotective effects, including reducing infarct
played a cardioprotective effect which conferred to reduce the in-
pathological progress while injection of BHB before ischemia dis-
tinction of ketone body metabolism served as energy supplementary.
However, it was not enough for maintaining in the long-last pe-
period of I/R injury. Whether extra-providing ketone body enabled
to preserve cardiac function when experienced I/R injury or other
cardiomyopathies.

Studies of Parkinson’s diseases showed BHB exhibited neu-
roprotective effects via mitochondrial respiratory and ATP
production improvement [8]. Moreover, BHB was served as an
endogenous and specific inhibitor of histone deacetylases that
increased Foxo3a and Mt2 promoter histone acetylation, contrib-
uting to protection against oxidative stress [9]. In aspect of heart
failure, BHB acted as not only an energy carrier but also a signal-
regulator in cardiac pathological progress. Treatment of BHB
apparently attenuated ROS production and cellular apoptosis in
response to H2O2-induced oxidative stress [10]. ACAC, 3 mM, has
also been served as a neuroprotective agent to retinal ganglion
cells (RGC) against neurodegeneration induced by NMDA [11]
and protects hippocampal neurons against glutamate-induced
toxicity by energy metabolism-related machenism [12]. In ad-
dition, SCOT-Heart-KO mice displayed more susceptible to
myocardial pressure and oxidative stress, suggesting an essential
role of SCOT-mediated ketone body signaling in cellular energy
metabolism [13].

Nicorandil, a KATP channel opener, had been demonstrated ex-
hibiting good cardioprotective effects, including reducing infarct
size, improving the recovery of myocardial contractile function and
preventing oxidative stress-induced cellular apoptosis [14,15].
In addition, previous study had shown nicorandil attenuated IRI
through PI3K/Akt signaling pathway to inhibit ER-stress-induced
apoptosis [16]. However, whether nicorandil displayed the cardio-
protective effects through the ketone body metabolism in H/R-
induced cardiomyocytes was rarely studied.

In our study, we performed in vitro models to evaluate the
effects of nicorandil on H/R-induced cytotoxicity. Nicorandil
increased cellular and mitochondrial viability in H9c2 cells ex-
posed to H/R. Meantime, nicorandil decreased ROS production,
allievated calcium overloading and reduced cellular apoptosis in
mitochondria-mediated proapoptotic pathway. In crucial, nicor-
adil pretreatment upregulated protein and gene expressions
of ACAT1 and OXCT1, and either of ketone body metabolism,
which promisingly characterized the potential activities of KATP
channel openers on ketone body metabolism.

METHODS

Cell culture

Rat H9c2 cardiomyocyte cell line was purchased from the
American Type Culture Collection (CRL1446, ATCC, USA). H9c2 cells were cultured in high glucose (4,500 mg/l) Dulbecco’s
Modified Eagle Medium (DMEM) composed of 10% fetal bovine
serum (FBS) and 1% v/v 100 U/ml penicillin and streptomycin
(Gibco, Oklahoma, USA) in a humidified incubator containing 5%
CO2 at 37°C.

Pharmacological interventions

For cellular treatment, nicorandil (Sigma-Aldrich, St. Louis,
MO, USA) pretreated for 24 h and H/R were performed when
cells reached 80-90% confluency. H9c2 cells were divided into
5 groups: i) control, cultured in normoxia (20% O2, 5% CO2); ii)
H/R alone; iii) H/R+nicorandil (25 µM); iv) H/R+nicorandil (50 µM); and v) H/R+nicorandil (100 µM).

In vitro model of H/R

Hypoxia in H9c2 cells was induced by replacing the normoxia
medium with Krebs–Ringer Bicarbonate (KRB) buffer that
consisted of 115 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 24 mM
NaHCO3, 1.2 mM KH2PO4, 1.2 mM MgSO4, 10 mM Hepes and
0.01% BSA, and placing cells into a chemical hypoxia system (BD,
USA) that consumed oxygen rapidly to induce hypoxic condition.
After 4 h hypoxia, H9c2 cells were subjected to reoxygenation by
replacing the KRB buffer with cultural medium for 12 h.

Cell viability

Cell viability of H9c2 cells was determined by measuring the
absorbance of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazo-
lium bromide (MTT) purchased from Sigma-Aldrich (St. Louis,
MO, USA). Cells were seeded in 96-well microplates at a density
of 1×104 cells per well. After pharmacological treatment, cells
were exposed to H/R and 100 µl cultural medium containing
MTT (5 mg/ml, Invitrogen, USA) at a final concentration of 500
µg/ml in PBS was added to the plates (10 µl/well) and incubated
for an additional 4 h at 37°C. Then MTT solution was discarded
and DMSO (150 µl) was added to each well to solubilize forma-
zan crystals formed in viable cells. The absorbance was measure-
optical density at 570/650 nm on a Multi-Mode Detection Plat-
form (SpectraMax Paradigm, Molecular Devices, USA). Cell vi-
ability of control group was considered as 100%.

Mitochondrial viability

H9c2 cells were seeded in the dark 96-well microplate at a den-
sity of 1×10^6 cells per well. Cells were treated as described above. After treatments, the mitochondrial viability was evaluated by the mitochondrial viability assay kit (ab129732, Abcam, USA). The fluorescence was detected at 590 nm with an excitation wavelength of 550 nm. Mitochondrial viability of control group was considered as 100%.

**Apoptosis measurement**

H9c2 were seeded in 6-well plates (2×10^6 cells per well). Cells in the different treatment groups were harvested and resuspended in PBS. Following centrifugation at 1,000×g for 5 min, detached cells were collected and incubated with Annexin V-Fluorescein isothiocyanate (FITC) coupled with Annexin V protein and propidium iodide (PI) (Sigma-Aldrich, St. Louis, MO, USA) at room temperature in the dark for 15 min. Immediately after gently pipetting, samples were analyzed by flow cytometry by performing with a 488-nm laser coupled to a cell sorter. Apoptotic cells were characterized by high Annexin V binding and high PI staining.

**ROS and calcium measurement**

Mitochondrial ROS was measured by the DCFDA Cellular ROS Detection Assay Kit (Invitrogen, USA) according to the commercial protocol. Cellular calcium overloading was measured by Fluo-4, AM (Invitrogen, USA) fluorescent probe staining according to commercial protocol. After H/R, cells were washed with PBS 1 time and digested by Trypsin-EDTA. Resuspended cells with cultural medium and incubated with DCFDA or Fluo-4 probe for 30 min at 37°C in dark. The ROS production and calcium concentration in each group were detected using BD FACSAria III flow cytometer (BD, USA) by intensity of green fluorescence (Ex 488 nm/ Em 535 nm).

**Western blot**

H9c2 cells were lysed in ice-cold RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, Cell Signaling Technology, USA) with and proteinase inhibitor cocktail (Roche, Basel, Switzerland). The cell lysates were immediately centrifuged at 13,000 g for 15 min at 4°C and the supernatants were boiled with loading buffer for 10 min. The concentrations of total proteins were quantified by the Bio-Rad protein assay kit (Bradford method) (Bio-Rad, CA, USA). Equal amounts of proteins (30 μg/lane) were separated by 10% SDS-PAGE gels and transferred to NC membranes (pore size: 0.45 μm, Pall, BioTrace). The membranes were blocked in 5% non-fat milk in TBST (Tris-buffer saline with 0.05% Tween 20) for 1 h and incubated with ACAT1 (1:1000, Abcam, UK), OXCT1 (1:1000, Santa Cruz, USA), Bax and Bcl-2 (1:1000, Cell Signaling Technology, USA) primary antibodies overnight at 4°C. β-Actin (Santa Cruz, USA) was used as the loading control. This process was followed by 3 times TBST washes for 15 min and incubation with the secondary fluorescent antibodies (1:5000, Odyssey, USA) for 2 h at room temperature in dark. The fluorescent signals of bands were detected by the Odyssey infrared imaging system (Belfast, USA). The densities of bands were normalized to Actin.

**RNA extraction, reverse transcription, and quantitative real-time PCR**

Total RNA was obtained from the cultured H9c2 cells using FavorPrepTM Total RNA purification mini kit (Favorgen Biotech Corp., Pingtung, Taiwan). Tissues were lysed and homogenized in 300 μl of lysis buffer (RLT Buffer; Qiagen, Basel, Switzerland), using the Fast Prep 24 lyzer (MPbio, Lucerne, Switzerland). Total RNA of tissue was isolated on spin columns with silica-based membranes (RNasy Mini Kit; Qiagen), following the manufacturer's instructions. RNA was eluted with 30 μl of H2O. A small amount of purified RNA (1 μg) from cells was reverse transcribed in a volume of 20 μl using the RT High-Capacity RNA-to-cDNA Kit (Applied Biosystems, Rotkreuz, Switzerland). Synthesized cDNA was then stored at −20°C. Quantitative real-time PCR were performed with the ViiA™ 7 real-time PCR system (Applied Biosystems, Grand Island, NY, USA) using the Taq polymerase master mix FastStart Universal SYBR-Green Master Rox (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. Primer sequences quantified for mRNA were directed against ACAT1, OXCT1, as well as β-actin mRNA used as an endogenous control (primer sequences are listed in Table 1). The PCR mixture is comprised of 10 μl SYBR master mix, 0.5 μl forward primers, 0.5 μl reverse primers, 1 μg template and ddH2O makes up to 20 μl. The procedure of RCR is 50°C for 2 min, 95°C for 10 min, followed by 45 cycles of 95°C for 15 s, 60°C for 60 s. Gene expression level was based on the comparative CT value using the 2^−ΔΔCT method and normalized with β-actin.

| Table 1. Primer sequences |
|---------------------------|
| **Name** | **Forward** | **Reverse** |
| ACAT1 | 5’-ATGGCTGCCCTGCGGGTTCTA-3’ | 5’-CTACAGCTTCTCAATCAGCAG-3’ |
| OXCT1 | 5’-CTGGAGTCTTGGAGACGCGCAT-3’ | 5’-TCCGCACTCTCCTCCTTGT-3’ |
| β-Actin | 5’-GCTACAGCCTCAAACACCA-3’ | 5’-ATCGTACTCCCTGCTTGA-3’ |

www.kjpp.net Korean J Physiol Pharmacol 2019;23(1):37-45
Cellular BHB and ACAC determination

Cellular BHB concentrations were determined using a Colorimetric Assay Kit (Cayman Chemical Company, USA). The Cells (~18×10^6 cells) were collected with a rubber policeman and then centrifugated at 2,000 g for 10 min, 4°C. Cell pellets were resuspended in 1-2 ml of cold assay buffer, then sonicated with 20× at 1 s bursts and centrifugated at 10,000 g for 10 min, 4°C. Supernatants were removed, the pellets were resuspended in 1 ml of cold assay buffer and stored on ice. Each sample was measured in triplicate with 50 µl of the sample in each well, and reacted by adding 50 µl of the developer solution. Then incubated the plate at 25°C in the dark for 30 min and then read the absorbance at 445-455 nm using a microplate reader.

Cellular ACAC concentrations were determined using a Colorimetric Assay Kit (Abcam, UK). After different treatments, cell pellets were collected and resuspended with ddH_2O. Sample volumes were adjusted to 110 µl, 80 µl ACAC assay buffer and 10 µl ACAC substrate were added and mixed well. After incubation at 25°C for 15 min, the values of absorbance at OD 550 nm were measured in a kinetic mode.

Cellular succinate and acetyl-CoA determination

Cellular succinate concentrations were determined using a Colorimetric Assay Kit (BioVision, USA). In brief, H9c2 cells were homogenized rapidly and centrifuge at 10,000×g for 5 min. Collected the supernatants and mixed with reagents into 96-well plate. After 30 min incubation at 37°C, samples were measured at 450 nm. The values of control group were considered as 1.0.

Cellular ACAC concentrations were determined using a Colorimetric Assay Kit (Abnova, TaiWan) according to manufactory’s protocol. H9c2 cells were homogenized rapidly on ice and centrifuge at 10,000×g. Supernatants were collected and neutralized pH to 6-8 and diluted volume to 50 µl. Then mixed samples with 50 µl reaction mix to be tested with fluorescent detection by using Ex/Em=535/589. The values of control group were considered as 1.0.

Fig. 1. Effects of nicorandil on cell and mitochondrial viability in H/R-induced H9c2 cells. (A) Hypoxia/reoxygenation protocol and drug treatment. Nicorandil was pretreatment 24 h before H/R. H/R was induced by incubating cells in KRB buffer as hypoxia for 4 h followed by incubating cells in cultural medium as reoxygenation for 12 h. (B, D) Effects of Nicorandil (25, 50, 100 µM) on cell viability under normoxia or hypoxia conditioning determined by MTT assay. Data (n=3) were shown as the mean±SEM, NS: no significance. (C, E) Effects of nicorandil (25, 50, 100 µM) on mitochondrial viability under normoxia or hypoxia conditioning determined by mitochondrial viability assay. Data (n=3) were shown as the mean±SEM, ***p<0.001 vs. control group, **p<0.01 vs. H/R group, ***p<0.001 vs. H/R group.
Nicorandil upregulates ketone body metabolism

Statistics

Data were analyzed by using GraphPad Prism 5.0, all data were expressed as the means±SEM. Student’s t-test was used to analyze difference between 2 groups. Statistical significance was accepted as p<0.05.

RESULTS

Nicorandil protected cardiomyocytes against H/R-induced cytotoxicity

To examine whether nicorandil had anti-H/R effect, we used a well-established H/R model that consisted of 4 h hypoxia followed by 12 h reoxygenation as shown in Fig. 1A. At first, MTT assays and mitochondrial viability assay were performed to evaluate cytotoxicity of nicorandil, and the control was used as a maximum reference (100%) to calculate the effects of nicorandil (25, 50, 100 μM) on cell and mitochondrial viability. After 24 h treatment, increasing concentrations of nicorandil (up to 100 μM) did not cause cellular cytotoxicity in H9c2 cells as shown in Fig. 1B. Consistently, different concentrations of nicorandil showed no significant effect on mitochondrial viability (Fig. 1C).

Subsequently, H/R significantly decreased the cell and mitochondrial viability over 50% compared with control group (100%), respectively. Increasing concentrations of nicorandil treatment enhanced cardiomyocytes survival after H/R in a dose-dependent

![Fig. 2. Effects of nicorandil on cellular apoptosis, ROS production and calcium overloading in H/R-induced H9c2 cells.](image-url)

(A, B) Effects of nicorandil (25, 50, 100 μM) on cellular apoptosis was detected by PI and Annexin V double staining evaluated by flow cytometry. Data (n=3) were presented as mean±SEM. ***p<0.001 vs. control group, **p<0.01 vs. H/R group, ***p<0.001 vs. H/R group. (C) ROS production was detected by H$_2$DCFDA probe staining and evaluated by flow cytometry. Data (n=3) were presented as mean±SEM. ***p<0.001 vs. control group, **p<0.01 vs. H/R group, ***p<0.001 vs. H/R group. (D) Calcium concentration was detected by Fluo-4 AM staining and evaluated by flow cytometry. Data (n=3) were presented as mean±SEM. ***p<0.001 vs. control group, **p<0.01 vs. H/R group, ***p<0.001 vs. H/R group. (E, F) The expression of Bcl-2 and Bax were detected by western blotting. β-Actin as a loading control. Data (n=3) were presented as mean±SEM. ***p<0.001 vs. control group, *p<0.05 vs. H/R group, ***p<0.001 vs. H/R group.
manner, showing a maximum of 77% cell viability and 78% mitochondrial viability with 100 µM nicorandil (Figs. 1D and E).

Nicorandil suppressed cellular apoptosis and oxidative stress in H9c2 cells exposed to H/R

Quantitative analysis using flow cytometry further confirmed that the apoptotic index (percentage of cells in early apoptosis plus late apoptosis) was markedly increased in H/R group (more than 40%) compared with that of control group (less than 10%). However, a decrease in the apoptotic rate was observed in H9c2 cells pretreated with nicorandil (Figs. 2A and B). The effect of nicorandil at the concentration of 100 µM decreased apoptotic rate to less than 20%.

Next, mitochondrial ROS was measured by the DCFDA fluorescent probes staining. H9c2 cells exposed to H/R resulted in significantly enhancement of ROS level compared with the control group. Treatment of nicorandil at the concentration of 25 µM significantly suppressed ROS level, and nicorandil at the concentration of 100 µM abolished H/R-induced ROS generation in large extent (Fig. 2C). Moreover, investigation was employed to determine whether the cardioprotective effect of nicorandil was related to the suppression of intracellular calcium overloading after H/R. Fig. 2D showed a significant decrease of calcium concentration in nicorandil groups compared with H/R group.

To further explore the potential apoptotic signaling in protective effect of nicorandil against H/R-induced cytotoxicity, the expressions of Bax and Bcl-2 were measured by western blotting. As shown in Fig. 2E, compared with the normal group, the expression of Bcl-2 decreased in the H/R group while the expression of Bax did not change, showing the decreased ratio of Bcl-2 to Bax in H/R group. Pretreatment of nicorandil increased the protein expressions of Bcl-2 and the ratio of Bcl-2 to Bax dose-dependently, comparing with H/R group (Figs. 2E and F).

Nicorandil up-regulated ACAT1 and OXCT1 expressions in H9c2 cells exposed to H/R

To demonstrate the potential of nicorandil on ketone body metabolism, we evaluated the expressions of ACAT1 and OXCT1 in H9c2 cells induced by H/R. Firstly, immunoblot analysis showed decreasing protein levels of ACAT1 and OXCT1 in H9c2 cells induced by H/R. Interestingly, nicorandil significantly increased the protein levels of ACAT1 and OXCT1 in dose-dependent manner (Figs. 3A and B). Then we further confirmed with the mRNA expression of ACAT1 and OXCT1. After H/R, ACAT1 and OXCT1 mRNA expressions were significantly decreased. Changes in these mRNA levels were consistent with the up-regulation of protein levels, nicorandil enhanced mRNA expressions of ACAT1 and OXCT1 with a great extent comparing with H/R group (Fig. 3C).

Nicorandil up-regulated ketone body metabolism in H9c2 cells exposed to H/R

In addition, we performed detection of BHB and ACAC concentration to examine the effects of nicorandil in H/R-induced H9c2 cells. BHB concentration was decreased significantly in H/
Nicorandil upregulates ketone body metabolism

R group, and nicorandil up-regulated BHB in H/R-induced H9c2 cells (Fig. 4A). Meanwhile, ACAT level reduced significantly in H/R group, followed by a significant augmentation in nicorandil group in dose-dependent manner (Fig. 4B). The combined analysis (ACAC+BHB) presented the similar decent when compared with the expressions of ACAT1 and OXCT1 that demonstrated a significant elevation of ketone body metabolism in nicorandil pretreated H9c2 cells in expose to H/R.

**DISCUSSION**

Nicorandil had been demonstrated protected heart and brain against ischemia/reperfusion injury by reducing cell apoptosis. As nicorandil is a mitochondrial K_{ATP} channel opener, it presents preconditioning effects and maintains energy metabolism when experiencing lethal injury. However, even if nicorandil could help mitochondria for their oxidative phosphorylation process, it was not enough for normal energy consumption, especially in reperfusion period, in which large amount of ROS produced and electron transport chain would be ineffective. Taking it for consideration, the reason why nicorandil can still display a good

---

Fig. 4. Effects of nicorandil on ketone bodies productions in H/R-induced H9c2 cells. (A) The concentration of β-hydroxybutyrate (BHB) in cell extractions. Data (n=3) were presented as mean±SEM. ###p<0.001 vs. control group, **p<0.01 vs. H/R group, ***p<0.001 vs. H/R group. (B) The concentration of acetoacetate (ACAC) in cell extractions. Data (n=3) were presented as mean±SEM. ###p<0.001 vs. control group, ***p<0.001 vs. H/R group.

Fig. 5. Effects of nicorandil on productions of acetyl-CoA and succinate in H/R-induced H9c2 cells. (A) The concentration of acetyl-CoA in cell extractions. Data (n=3) were presented as mean±SEM. ###p<0.001 vs. control group, **p<0.01 vs. H/R group. (B) The concentration of succinate in cell extractions. Data (n=3) were presented as mean±SEM. ###p<0.001 vs. control group, **p<0.01 vs. H/R group, ***p<0.001 vs. H/R group.

---

To further evaluate the activities of ACAT1 and SCOT1, we detected the concentrations of their metabolic products, succinate and acetyl-CoA. In cells exposed to H/R, the amounts of succinate and acetyl-CoA decreased significantly, while pretreatment of nicorandil significantly increased the amounts of succinate and acetyl-CoA, suggesting the upregulated expressions of ACAT1 and SCOT1 contributed to enhanced ketone body metabolism (Figs. 5A and B).
effect on I/R injury probably because of a supplementary energy metabolism system—ketone body metabolism. In our study, we used in vitro model of hypoxia/reoxygenation (H/R) in H9c2 cell line to mimetic in vivo model of ischemia/reperfusion injury. After experiencing 4 h hypoxia and 24 h reoxygenation, H9c2 cell viability decreased more than 50%, as well as mitochondrial viability, demonstrating it was applicable for the subsequent study. Pretreatment of nicorandil displayed cardioprotective effects evaluated by MTT assay and mitochondrial viability assay. To further evaluate whether nicorandil could reduce cellular apoptosis, we performed Annexin V/PI double staining assay to detected cellular apoptotic rate after H/R. Results analyzed by flow cytometry showed there was a significantly increasing population of apoptotic cells (over 40%), comparing with control group (less than 10%). Pretreatment of nicorandil decreased cellular apoptotic rate dose-dependent (less than 20% in 100 µM nicorandil treatment group). Taken together, our in vitro model of H/R major caused H9c2 cells death by inducing cellular apoptosis and nicorandil reduced myocardial injury by increasing mitochondrial viability and preventing cellular apoptosis.

Oxidative stress and calcium overloading were considered as two main hypotheses to explain the pathogenetic progress of ischemia/reperfusion injury. In general, oxidative stress, associated with extra-formation of reactive oxygen species (ROS), contributed to modification of phospholipids and proteins and further changed membrane permeability. That influences membrane ion channels, like Na+/K+ pump and Ca2+ pump, which impaired the balance of internal and external concentration of Ca2+, leading to calcium overloading [17]. Our in vitro model of H/R significantly increased cellular ROS production and caused calcium overloading in H9c2 cells. Pretreatment of nicorandil had the ability to reduce the excessive production of ROS and calcium overloading dose-dependently, indicating nicorandil protected cardiomyocytes against H/R by alleviating oxidative stress.

Beyond the theory that oxidative phosphorylation would lose its function for a long-term period even when oxygen was resupplied to cardiomyocytes [1], there was, doubtlessly, other energy production pathways to maintain cellular metabolism for cell survival. Whether improving these metabolisms' efficiency could address the issue of energy supplying to keep cell survival when experiencing H/R. One of energetic sources that feed cells in oxygen-existing condition is ketone body metabolism. Ketone bodies, served as supplementary energy source for energy-consumption tissues in times of fasting and exercise [2,3], were produced by fatty acids via mitochondrial β-oxidation in liver. The fatty acids were firstly metabolized to acetyl-CoA and then produced to ACAC, which was the precursor of the other ketone bodies, acetone and BHB. When taken up by heart, BHB will converted back into ACAC. Meantime, ACAC obtained a CoA donated by Succinyl-CoA to form acetoacetyl-CoA, catalyzed by OXCT1 (also known as SCOT). Then acetoacetyl-CoA were going to be converted to two acetyl-CoA by ACAT1 and participated into tricarboxylic acid cycle for ATP production [18]. Take insight into cardiac pathogenesis, while the role of fatty acids had been explored decades, the dynamics of ketone body metabolism in regulation of myocardial energy utilization and mitochondrial biogenetics were rarely studied when facing external stresses. Rebecca C. Schugar’s study demonstrated ketone body oxidation play an important role in free radical homeostasis that promoted myocardial response to pressure overloading [13]. In the failing heart, energy demand was considered as the most important problem as well as the cardiac capacity to utilize other fuels, such as ketone body. In Gregory Aubert’s study, they used quantitative mitochondrial proteomics to identify dysfunctional proteins during the development of heart failing. They found proteins involved in ketone body metabolism were downregulated in failing heart. Moreover, they uncovered that ketone bodies oxidation reduced heart failing in an ex vivo model of isolated perfused heart, indicating they acted as a crucial fuel source for energy metabolism [19]. In extent of failing human heart, ketone body utilization performed as an alternative fuel and adaptive metabolic products [20]. In our study, the protein expressions of ACAT1 and OXCT1 decreased in H9c2 cells exposed to H/R. Pretreatment of nicorandil significantly upregulated the protein expressions of ACAT1 and OXCT1 and either of their mRNA expressions. Further quantification of ketone bodies showed nicorandil also upregulated two major metabolic products, BHB and ACAC. Moreover, pretreatment of nicorandil significantly increased the amounts of succinate and acetyl-CoA, suggesting the upregulated expressions of ACAT1 and SCOT1 contributed to enhanced ketone body metabolism.

Beyond basic acknowledgement between ketone body and energy metabolism, novel insights of ketone body functions were discovered. Recent study showed gut microbiota increased ketone utilization during fasting by using functional genomic, biochemical, and physiologic assays, implying the benefit provided by gut microbiota in myocardial ketone body metabolism [21]. Ketone body also suppressed autophagic elimination in neurons to prevent cell death induced by glucose deprivation. In the presence of BHB, the level of LC3-II and p62 declined in neurons in expose to glucose deprivation [22]. Our finding gives a new insight into the effect of nicorandil on cardiac injury and cellular apoptosis via regulation of ketone body metabolism, by which these results enrich our view to better understand the complex energy metabolisms in heart when experiencing I/R injury and new strategy for drug discovery.

ACKNOWLEDGEMENTS

This research was supported by the Clinical Study on Pharmacokinetics of Three Cephalosporins in Cerebrospinal Fluid Based on HPLC Fund 2017SF-257.
CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
2. Silachev DN, Plotnikov EY, Pevzner JB, Zorova LD, Babenko VA, Zorov SD, Popkov VA, Jankauskas SS, Zinchenko VP, Sukhihik GT, Zorov DB. The mitochondrion as a key regulator of ischaemic tolerance and injury. Heart Lung Circ. 2014;23:897-904.
3. Abete P, Testa G, Cacciato F, Della-Morte D, Galizia G, Langelotto A, Rengo F. Ischemic preconditioning in the younger and aged heart. Aging Dis. 2011;2:138-148.
4. Kloner RA, Rezkalla SH. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovac Res. 2006;70:297-307.
5. Fukao T, Mitchell G, Sass JO, Hirai T, Orii K, Aoyama Y. Ketone body metabolism and its defects. J Inherit Metab Dis. 2014;37:541-551.
6. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304:H1060-H1076.
7. Faria MH, Muniz LR, Vasconcelos PR. Ketone bodies metabolism during ischemic and reperfusion brain injuries following bilateral occlusion of common carotid arteries in rats. Acta Cir Bras. 2007;22:125-129.
8. Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Yan SD, Naini A, Vila M, Jackson-Lewis V, Ramasamy R, Przedborski S. D-β-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. 2003;112:892-901.
9. Shimazu T, Hirshey MD, Newman J, Weh, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339:211-214.
10. Nagao M, Toh R, Ino Y, Mori T, Nakajima H, Hara T, Hiroto J, Satomi-Kobayashi S, Shinke T, Tanaka H, Ishida T, Hirata K. β-Hydroxybutyrate elevation as a compensatory response against oxidative stress in cardiomyocytes. Biochem Biophys Res Commun. 2016;475:322-328.
11. Thaler S, Choragiwicz TJ, Rejdak R, Fiedorowicz M, Turski WA, Tuhladowicz-Bielak M, Zrenner E, Schuettauf F, Zarnowska T. Neuroprotection by acetocacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat–possible involvement of kynurenic acid. Graefes Arch Clin Exp Ophthalmol. 2010;248:1729-1735.
12. Massieu L, Haces ML, Montiel T, Hernández-Fonseca K. Acetocacetate protects hippocampal neurons against glutamate-mediated neuronal damage during glycolysis inhibition. Neuroscience. 2003;120:365-378.
13. Schugar RC, Moll AR, Andrê d’Avignon D, Weinheimer CJ, Kovacs A, Crawford PA. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol Metab. 2014;3:754-769.
14. Li W, Wu N, Shu W, Jia D, Jia P. Pharmacological preconditioning and postconditioning with nicorandil attenuates ischemia/reperfusion-induced myocardial necrosis and apoptosis in hypercholesterolemic rats. Exp Ther Med. 2015;10:2217-2225.
15. Ishii H, Ichimiyama S, Kanashiro M, Amano T, Imai K, Murohara T, Matsubara T. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112:1284-1288.
16. Wu H, Ye M, Yang J, Ding J, Yang J, Dong W, Wang X. Nicorandil protects the heart from ischemia/reperfusion injury by attenuating endoplasmic reticulum response-induced apoptosis through PI3K/Akt signaling pathway. Cell Physiol Biochem. 2015;35:2320-2332.
17. Dhall NS, Elmoselhi AB, Hata T, Makino N. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res. 2000;47:446-456.
18. Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25:42-52.
19. Aubert G, Martin OF, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SL, Krüger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133:698-705.
20. Bedi KC Jr, Snyder NW, Brandimarto I, Aziz M, Mesaros C, Worth AJ, Wang LL, Javaheri A, Blair IA, Margulies KB, Rame JE. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 2016;133:706-716.
21. Crawford PA, Crowley JR, Sambandam N, Muegge BD, Costello EM, Hamady M, Knight R, Gordon JJ. Regulation of myocardial ketone body metabolism by the gut microbiota during nutrient deprivation. Proc Natl Acad Sci U S A. 2009;106:11276-11281.
22. Camberos-Luna L, Gerónimo-Ólvera C, Montiel T, Rincon-Heredia R, Massieu L. The ketone body, β-hydroxybutyrate stimulates the autophagic flux and prevents neuronal death induced by glucose deprivation in cortical cultured neurons. Neurochem Res. 2016;41:600-609.